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Identity 
Other names: c-Ha-ras 1 
HGNC (Hugo): HRAS 
Location: 11p15.5 
 
Probe(s) - Courtesy Mariano Rocchi, Resources for Molecular 
Cytogenetics. 




H-ras splicing variants: alternative splicing of H-ras precursor 
mRNA leads to the two transcripts p19 and p21 which differ by 
the ex- or inclusion of the Intron D exon (IDX); Exons that 
encode protein are shown as black boxes, untranslated exons 
as white boxes; the upstream untranslated exon is indicated as 
Exon -1. 
Description 
Consists of six exons, spread over 6.6 kb of genomic 
DNA. 
Transcription 
Alternative RNA splicing reveals two different 
transcripts (see Fig); if the intron D exon (IDX) is
skipped exon 4 is directly joined to exon 3. 
Note 
To be quoted is the existence of a pseudogene, c-Ha-ras 
2, inactivated, processed pseudogene which is located 




170 amino acids; 19kDa; shares a common effector 
region with regular RAS proteins; absence of residues 
152-165, abrogating the GDP/GTP binding, and lack of 
a cysteine residue in the carboxy-terminus preventing 
the posttranslational modifications essential for the 
attachment of RAS proteins to the cytoplasmic 
membrane. 
Expression 
p19H-ras is expected to be produced at a much higher 
level than p21H-ras; the surprising low abundance of 





No oncogenic ability; it has been assumed, that p19H-
ras might act as a antagonist to p21H-ras; due to the 
intact effector region it would interact constitutively 
with candidate effector molecules or regulators such as 
GAP, thereby suppressing the biological function of 
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p21H-ras; additionally the expression of p19H-ras was 
found to limit the production of p21H-ras. 
Homology 
RAS, RAL, RAC, RHO, RAP, and RAB. 
Description 
p21H-ras 





Anchored to the inner surface of the plasma membrane. 
Function 
Analogously to other GTP-binding proteins (such as 
Translation Elongation Factor EFTu or signal 
transducing G-Proteins) RAS proteins are involved in 
signal transduction pathways. 
Homology 
Ras gene family is part of the ras superfamily including 
the mammalian RAS, RAL, RAC, RHO, RAP, and 
RAB gene families and the yeast homologs like SEC4 
and YPT1 genes; genes encode small monomeric 
proteins of low molecular mass (20-30 kDa) which 
share at least 30% homology with RAS proteins. 
Implicated in 
Tumor (frequency of H-RAS mutations); 
references in Full Bibliography 
Stomach (0-40%) 





Head and neck (0-30%) 
Endometrium (5%) 
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